CareDx Divests Lab Products Business for $170M, Focuses on Precision Medicine Testing

Transaction Sharpens CareDx's Focus on Core Testing Services and Patient Solutions, Improves Financial Flexibility

Apr. 15, 2026 at 9:40pm

Got story updates? Submit your updates here. ›

A photorealistic studio photograph featuring a polished metal medical device, a glass vial, and a stack of medical test results files arranged elegantly on a clean, white background, symbolizing CareDx's focus on precision diagnostics and patient care.A refined, minimalist still life captures the essence of CareDx's precision medicine solutions for transplant patients.Brisbane Today

CareDx, Inc., a leading precision medicine company focused on transplant patients, announced it has entered into a definitive agreement to divest its Lab Products business to EuroBio Scientific for $170 million in cash. The transaction is expected to simplify CareDx's operating model and support its focus on Precision Medicine Testing Services and Patient and Digital Solutions, which saw 48% and 33% year-over-year revenue growth respectively in Q1 2026.

Why it matters

The divestiture allows CareDx to strategically focus on its core testing services and patient solutions, where its solutions-selling strategy is working. As a global IVD kit business, the Lab Products segment operated under a different model than CareDx's U.S.-based precision medicine offerings, so the sale is intended to simplify the company's structure and support disciplined capital allocation.

The details

CareDx's Lab Products business includes IVD PCR kits for HLA typing and monitoring assays for transplant recipients globally. EuroBio Scientific, which has partnered with CareDx since 2014, will acquire the Lab Products segment and continue providing service to IVD customers worldwide. In return, CareDx will gain the exclusive rights to distribute its post-transplant monitoring IVD tests in North America.

  • The transaction is expected to close by the end of CareDx's third quarter of 2026.
  • CareDx will provide transition services to EuroBio Scientific for at least 6 months at EuroBio Scientific's expense.

The players

CareDx, Inc.

A leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers.

EuroBio Scientific

A major player in the field of specialty in vitro diagnostics, involved in research, marketing, and distribution of diagnostic tests in transplantation, immunology, and infectious diseases.

Got photos? Submit your photos here. ›

What they’re saying

“This divestiture allows us to strategically focus on our core Testing Services and Patient and Digital Solutions, where our solutions-selling strategy is working.”

— John Hanna, President and CEO of CareDx

What’s next

The transaction, including the sale of CareDx's Swedish entity, requires Swedish regulatory review. The parties anticipate the transaction to close by the end of CareDx's third quarter, 2026.

The takeaway

By divesting its Lab Products business, CareDx can sharpen its focus on its core precision medicine testing services and patient solutions, which have seen strong growth, while simplifying its operating model and improving financial flexibility to support long-term strategic investments.